All In Biotech

NDA 021060 · Esteve

Prialt

Ziconotide Acetate · Intrathecal

NovelPriority review

Last checked: Nov 20, 2026Latest source record: Mar 16, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2004

Dec 28, 2004

Approved uses

1

Original approval plus efficacy supplements

Registered trials

9

3 Phase 3, 2 recruiting

FAERS reports

2,435

1,162 serious, 121 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: NEUROPSYCHIATRIC ADVERSE REACTIONS PRIALT is contraindicated in patients with a preexisting history of psychosis. Severe psychiatric symptoms and neurological impairment may occur during treatment with PRIALT. Monitor all patients frequently for evidence of cognitive impairment, hallucinations, or changes in mood or consciousness. Discontinue PRIALT therapy in the event of serious neurological or psychiatric signs or symptoms. WARNING: NEUROPSYCHIATRIC ADVERSE REACTIONS See full prescribing information for complete boxed warning Severe psychiatric symptoms and neurological impairment may occur during treatment with PRIALT. Do not treat patients with a pre-existing history of psychosis with PRIALT

What it is approved for

From the label in effect Sep 15, 2026.

PRIALT (ziconotide) solution, intrathecal infusion is indicated for the management of severe chronic pain in adult patients for whom intrathecal therapy is warranted, and who are intolerant of or refractory to other treatment, such as systemic analgesics, adjunctive therapies, or intrathecal morphine. PRIALT (ziconotide) solution, intrathecal infusion is an N-type calcium channel antagonist indicated for the management of severe chronic pain in patients for whom intrathecal therapy is warranted, and who are intolerant of or refractory to other treatment, such as systemic analgesics, adjunctive therapies, or intrathecal morphine. ( 1 )

Mechanism: Ziconotide binds to N-type calcium channels located on the primary nociceptive (A-δ and C) afferent nerves in the superficial layers (Rexed laminae I and II) of the dorsal horn in the spinal cord. Although the mechanism of action of ziconotide has not been established in humans, results in animals suggest that its binding blocks N-type calcium channels, which leads to a blockade of excitatory neurotransmitter release from the primary afferent nerve terminals and antinociception.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 28, 2004 Original approval · Type 1 - New Molecular Entity · priority review NovelLabelLetterReview
4 products under this application
  • PRIALT · ZICONOTIDE ACETATE 500MCG/20ML (25MCG/ML) · INJECTABLE, INTRATHECAL · Prescription
  • PRIALT · ZICONOTIDE ACETATE 500MCG/5ML (100MCG/ML) · INJECTABLE, INTRATHECAL · Prescription
  • PRIALT · ZICONOTIDE ACETATE 100MCG/1ML (100MCG/ML) · INJECTABLE, INTRATHECAL · Prescription
  • PRIALT · ZICONOTIDE ACETATE 200MCG/2ML (100MCG/ML) · INJECTABLE, INTRATHECAL · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Ziconotide" as an intervention, any sponsor and status, largest first.

All 9 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • pain362
  • device issue313
  • off label use302
  • drug ineffective241
  • confusional state205
  • nausea205
  • hallucination168
  • dizziness157
  • headache136
  • hallucination, auditory133
  • memory impairment104
  • fall101

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200575
200697
2007102
200828
200930
201037
201150
201266
201361
201496
2015118
2016392
2017304
2018268
2019211
202026
2021125
202282
202383
202470
202574
202639

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Prialt (Ziconotide Acetate)

2024 spending

$58K

Beneficiaries

n/a

15 claims

Per beneficiary

n/a

$747.77 per unit

View as table
YearSpending
2020$85,297
2021$81,902
2022$107,552
2023$99,046
2024$57,579

Part B: Prialt (Ziconotide Acetate) · HCPCS J2278

2024 spending

$3.6M

Beneficiaries

322

1,120 claims

Per beneficiary

$11,278

2024 ASP limit $9.38 per unit

View as table
YearSpending
2020$4,916,504
2021$4,488,250
2022$4,158,857
2023$3,671,203
2024$3,631,398

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 19 on PubMed

Sponsor: Esteve

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.